Publications

350 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease

The National Health Care Institute has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product ...

Report | 03-02-2021

GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria

The National Health Care Institute has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product ...

Report | 02-02-2021

GVS assessment oxybutynin intravesical solution (Vesolox®)

Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...

Report | 18-01-2021

GVS advice mexiletine (Namuscla®)

The National Health Care Institute has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable ...

Report | 13-01-2021

Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

Letter | 21-12-2020

GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

The National Health Care Institute has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product ...

Report | 16-12-2020

GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections

Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...

Report | 15-12-2020

GVS assessment - extension of further conditions for nintedanib (Ofev®)

The National Health Care Institute has completed its assessment of the possible extension of the further conditions for ...

Report | 15-12-2020

Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL

Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...

Report | 10-12-2020

GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis

The National Health Care Institute has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or ...

Report | 03-12-2020